Medical diagnostics company completes acquisition

Eric Strauss//April 14, 2015//

Listen to this article

Rosetta Genomics Ltd., an Israeli company with its U.S. headquarters in Princeton, announced Tuesday that it has completed the acquisition of a molecular diagnostics and services company that serves doctors and reference laboratories nationwide.California-based PersonalizeDx, also known as CynoGen Inc., was purchased for an undisclosed amount from Prelude Corporation, which is also based in California. Rosetta, which develops and provides microRNA and other molecular diagnostics, said the deal will give it proprietary tests for various cancers, commercial and laboratory operations, plus PersonalizeDx’s state-of-the-art clinical laboratory.

“We are delighted to complete this important, strategic acquisition and look forward to integrating PersonalizeDx into Rosetta Genomics,” Kenneth A. Berlin, CEO and president of Rosetta, said in a prepared statement. “There are multiple areas of product synergies between these two businesses, notably in urologic and lung cancers.”

ALSO ON NJBIZ:

Hackensack, Summit set to partner, create state’s largest physician group

Eisai details job cuts coming to Woodcliff Lake HQ

Luxury apartment building starts to rise in Hoboken